Search company, investor...
Mendor company logo


Founded Year



Asset Sale | AssetsPurchased

Total Raised


About Mendor

Mendor develops a portable all-in-one blood glucose meter and web-based software application for the daily management of diabetes. Mendor develops its products with the aim to help people with diabetes that require regular blood glucose monitoring.

Headquarters Location

Kägelstranden 16

Espoo, FI-02150,


+358 (0)9 315 77 300

Missing: Mendor's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Mendor's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Mendor

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mendor is included in 2 Expert Collections, including Diabetes.



1,904 items


Digital Health

10,347 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Mendor Patents

Mendor has filed 4 patents.

patents chart

Application Date

Grant Date


Related Topics




Diabetes, Blood tests, Body fluids, Insulin therapies, Actuators


Application Date


Grant Date



Related Topics

Diabetes, Blood tests, Body fluids, Insulin therapies, Actuators



Latest Mendor News

Capitainer awarded ISO certification for its QMS

Nov 11, 2020

Capitainer awarded ISO certification for its QMS Search for content, post, videos Capitainer has received the International Organization for Standards (ISO) 13485:2016 certification for its Quality Management System (QMS). ISO 13485 is designed specifically for medical device companies and commonly regarded as essential for accessing international markets. It comes as Capitainer enters a period of rapid expansion following the signing of key distribution agreements in the US and Europe for its highly accurate qDBS dried blood spot sampling system. Interest is strong across a wide range of  challenging applications from therapeutic drug monitoring, genomics anti-doping testing to COVID-19 testing, states the company. “We are delighted to have attained ISO 13485 for our Quality Management System. We are committed to developing the highest quality products at Capitainer and our team has worked hard to achieve this milestone. Both the FDA and EU require a quality system and this award will accelerate commercialization,” says Christopher Aulin, CEO of Capitainer. January 30, 2015 Finnish diabetes technology and solution company Mendor has signed a contract with the Finnish City of Tampere to provide Mendor ONE mobile health diabetes management solutions for people with type 1 diabetes at the Tampere diabetes outpatient clinic. Mendor ONE carries a cellular enabled blood glucose meter, cloud software to… February 16, 2017 Senzime has entered distribution agreements for the commercialization of TetraGraph with Wardray Premise, who will be the exclusive distributor in the UK and Ireland and LSR Healthcare who will be the exclusive distributor in Australia and New Zealand. Compensation to distributors will be paid on a “per-unit sold” basis, and… March 11, 2020 Medtech start-up, Capitainer, has announced that it has closed a share issue of SEK 15 million to commersialize its new dried blood spot sampling solution. Lead investors are Nordic Consumer Health and the US-based Wolf Family Trust, joined by a consortium of Nordic angel investors and Capitainer management. “The dried…

Mendor Frequently Asked Questions (FAQ)

  • When was Mendor founded?

    Mendor was founded in 2005.

  • Where is Mendor's headquarters?

    Mendor's headquarters is located at Kägelstranden 16, Espoo.

  • What is Mendor's latest funding round?

    Mendor's latest funding round is Asset Sale.

  • How much did Mendor raise?

    Mendor raised a total of $26.82M.

  • Who are the investors of Mendor?

    Investors of Mendor include Glucostratus, IPF Partners, Ilmarinen Pension Insurance, Finnvera, Biothom and 4 more.

  • Who are Mendor's competitors?

    Competitors of Mendor include BeatO, Zhiyun Health, DIABNEXT, Dnurse, Glooko and 12 more.

Compare Mendor to Competitors

Omada Health Logo
Omada Health

Omada Health delivers a digital behavioral medicine company. The company helps to protect patients from chronic conditions like heart disease and type 2 diabetes. It offers behavioral counseling by using insights about social networking, gaming, and behavioral science to motivate changes in lifestyle and deliver clinically-meaningful results. The company was founded in 2011 and is based in San Francisco, California.


Glymetrix aims to provide engagement strategies to motivate better diabetes management through the use of rewards and incentives. Glymetrix uses a game based interface to engage patients with a data model at the core of the system.

BeatO Logo

BeatO develops diabetes care and management application to manage and prevent health. It offers health monitoring, health insights, daily coaching from experts, health plans, nutrition support, lab tests, and pharmacy. The company offers smartphone glucometers and connected monitoring devices that help users monitor and get guidance for blood sugar, blood pressure, and other health vitals. It was founded in 2015 and is based in New Delhi, India.

Life In Control Logo
Life In Control

Curo Healthcare Technologies runs Life In Control, a digital diabetes management program. The Life in Control app, which is available both in Android and iOS platforms, is designed to connect doctors and patients to help patients better manage their glycemic status in collaboration with their doctors. It also analyzes patients' historical data to predict secondary complications aimed at preventing diabetes and promoting wellness.

InSpark Technologies Logo
InSpark Technologies

Our software provides impactful diabetes management insights at the right time; when people test their blood sugar levels. We can present feedback on undesirable patterns occuring in upcoming problem areas of the day, patterns of glucose variability, risk of hypoglycemia, estimated HbA1c, and insulin sensitivity on monitoring devices or on connected mobile phones.

Emperra Logo

Emperra is a startup that creates a digital diabetes management solution. The company's Esysta technology allows the complete capture of all relevant data such as insulin doses, blood sugar levels and carbohydrates.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.